A phase II trial of dociparstat sodium (CX-01) in patients with myelodysplastic syndrome

Trial Profile

A phase II trial of dociparstat sodium (CX-01) in patients with myelodysplastic syndrome

Recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Apr 2017

At a glance

  • Drugs Dociparstat sodium (Primary)
  • Indications Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Apr 2017 Status changed from planning to recruiting, according to a Cantex Pharmaceuticals media release.
    • 11 Apr 2017 New trial record
    • 04 Apr 2017 This trial is expected to begin in 2017, according to a Cantex Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top